We investigate how inherited mutations in cancer predisposition genes BRCA1,BRCA2, RAD51, RAD51 paralogs, PALB2, and ATM –compromise the protection of replicating DNA and drive hereditary breast, ovarian, pancreatic, and prostate cancers. Using electron microscopy, cryo-EM, and biochemical reconstitution, we identify the molecular vulnerabilities of DNA repair-deficient cancer cells that can be exploited by targeted therapies including PARP inhibitors and POLθ inhibitors, and we develop structural approaches to reclassify variants of uncertain significance in cancer susceptibility genes.
Vincenzo Costanzo is Full Professor of General Pathology at the University of Milan and Senior Group Leader at IFOM ETS, where he directs the DNA Metabolism programme. After training at Columbia University and founding his lab at Cancer Research UK’s Clare Hall Laboratories, he moved to IFOM in 2013. An elected EMBO Member and recipient of two ERC grants, his discovery that BRCA2 and RAD51 protect replicating DNA from degradation fundamentally changed our understanding of why BRCA mutation carriers develop cancer and how their tumours respond to therapy.
Antonie Aze (Postdoc), Hervé Técher (Postdoc), Arun M. Kolinjivadi (PhD), Anjali Mann (PhD), Andrea Gnocchi (PhD), Christelle El Kai (PhD), Sina Atashpaz (Postdoc), Vincenzo Sannino (Postdoc).